Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
Oncology Reports
Tak, Eunyoung E; Kim, Minhee M; Cho, Youngra Y; Choi, Sueun S; Kim, Jihun J; Han, Buhm B; Kim, Hyung-Don HD; Jang, Chloe Soo-Hyun CS; Kim, Jeong Eun JE; Hong, Yong Sang YS; Kim, Sun Young SY; Kim, Tae Won TW